Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | TFAP4 | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-06 |
mRNA | CELF4 | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-06 |
mRNA | ZNF497 | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-06 |
mRNA | SPTSSB | CTRPv2 | pan-cancer | AAC | -0.15 | 4e-06 |
mRNA | TRA2A | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-06 |
mRNA | UHRF1 | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-06 |
mRNA | FSD1 | CTRPv2 | pan-cancer | AAC | 0.18 | 4e-06 |
mRNA | HM13 | CTRPv2 | pan-cancer | AAC | -0.16 | 4e-06 |
mRNA | AS3MT | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-06 |
mRNA | SENP1 | CTRPv2 | pan-cancer | AAC | 0.16 | 4e-06 |